NAV

Acetylcysteine zidrimer

Identification

Generic Name
Acetylcysteine zidrimer
DrugBank Accession Number
DB16496
Background

Not Available

Type
Small Molecule
Groups
Investigational
Synonyms
  • Acetylcysteine zidrimer
  • Dendrimer N-acetyl-cysteine
  • OP 101
  • OP-101
External IDs
  • OP-101
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

OP-101 is a novel compound that involves n-acetyl cyseine covalently bonded to an inactive dendrimer. In preclinical models, it was shown that OP-101 is selectively taken up by activated microglia, and localizes in areas wehre there is neuroinflammation. In these activated neural cells, OP-101 releases n-acetyl cysteine and helps reduce oxidative stress and inflammation. In multiple animal models, OP-101 was shown to normalize reactive macrophages, shut down cytokine cascades, and attenuate hyperinflammation. Thus, in May 2020, Orpheris, a subsidiary of Ashvattha Therapeutics and the developer of the compound, is pursuing a Phase 2 clinical study on the safety, pharmacokinetics, and efficacy of OP-101 in patients exhibiting severe COVID-19 symptoms (NCT04458298).

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7JWF1EYH61
CAS number
2736440-65-4
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. External Link [Link]
  2. External Link [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentCoronavirus Disease 2019 (COVID‑19)1
1CompletedTreatmentHealthy Volunteers (HV)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at January 21, 2021 02:01 / Updated at June 20, 2023 09:00